The European health technology assessment has been started for the following three new oncology active substances:
- Savolitinib: For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Varegacestat: For the treatment of desmoid tumours in adults.
- Sonesitatug vedotin: For the treatment of adult patients with locally advanced, unresectable or metastatic adenocarcinoma of the stomach, the gastro-oesophageal junction (the junction between the oesophagus and the stomach) or the oesophagus.
Photo: Thijs ter Haar, CC BY 2.0